Status:
COMPLETED
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine. In addition, the study will also look at ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female, aged between 18 to 65 years (both inclusive) at the time of signing informed consent
- Body mass index (BMI) between 30.0 and 45.0 kg/m\^2 (both inclusive)
- Exclusion criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method
- Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions
Exclusion
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 4 2019
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT03842202
Start Date
February 15 2019
End Date
November 4 2019
Last Update
December 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Berlin, Germany, 14050